Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMUX Immunic, Inc.

Pre-Mkt 02-10 04:08:33 EST

0.7140

+0.0940

+15.16%

High0.7200	Low0.5900	Vol3.55M
Open0.6296	D1 Closing0.6200	Amplitude20.97%
Mkt Cap85.88M	Tradable Cap68.40M	Total Shares120.28M
T/O2.40M	T/O Rate3.71%	Tradable Shares95.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMUX","market":"US","secType":"STK","nameCN":"Immunic, Inc.","latestPrice":0.714,"timestamp":1770670800000,"preClose":0.62,"halted":0,"volume":3552283,"delay":0,"changeRate":0.1516129032258064,"floatShares":95793500,"shares":120284724,"eps":-0.8362,"marketStatus":"Pre-Mkt","change":0.094,"latestTime":"02-10 04:08:33 EST","open":0.6296,"high":0.72,"low":0.59,"amount":2403461.67644422,"amplitude":0.209677,"askPrice":0.713,"askSize":300,"bidPrice":0.65,"bidSize":199,"shortable":3,"etf":0,"ttmEps":-0.8362,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1397707200000,"exchange":"NASDAQ","adjPreClose":0.714,"postHourTrading":{"tag":"盘后","latestPrice":0.7289,"preClose":0.714,"latestTime":"19:57 EST","volume":41429,"amount":29587.675559,"timestamp":1770685072242,"change":0.0149,"changeRate":0.020868,"amplitude":0.076891},"volumeRatio":3.3684773195285262,"impliedVol":2.4519,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/IMUX/wiki","defaultTab":"wiki","newsList":[{"id":"2610328846","title":"Immunic Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610328846","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610328846?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:32","pubTimestamp":1770636720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 06:32 ET (11:32 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2608836391","title":"Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608836391","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608836391?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:30","pubTimestamp":1770204655,"startTime":"0","endTime":"0","summary":"Immunic Inc. has announced that it will present additional data from its phase 2 CALLIPER trial of vidofludimus calcium  in patients with progressive multiple sclerosis at the ACTRIMS Forum 2026, scheduled for February 5-7 in San Diego, California. The new data include MRI analyses showing reductions in both acute and chronic inflammatory disease activity, as well as subset data demonstrating reductions in EBV-specific T-cell receptor sequences, indicating potential broad-spectrum antiviral effects. The results will be available in poster presentations accessible on Immunic's website following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL5vxYhF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2608363677","title":"Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608363677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608363677?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:30","pubTimestamp":1770204610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUCBS67Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2607040278","title":"Insider Traders Lose US$42k As Immunic Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040278","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040278?lang=en_us&edition=fundamental","pubTime":"2026-01-30 19:43","pubTimestamp":1769773393,"startTime":"0","endTime":"0","summary":"The recent 11% drop in Immunic, Inc.'s ( NASDAQ:IMUX ) stock could come as a blow to insiders who purchased US$246.9k...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/insider-traders-lose-us42k-as-immunic-drops","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/insider-traders-lose-us42k-as-immunic-drops","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2601809814","title":"Immunic Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809814?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:06","pubTimestamp":1767794760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 09:06 ET (14:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2601848031","title":"Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2601848031","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601848031?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:06","pubTimestamp":1767733603,"startTime":"0","endTime":"0","summary":"Immunic Inc. is facing potential delisting from the Nasdaq Stock Market due to non-compliance with the minimum bid price requirement. The company’s stock price closed below $1.00 for 30 consecutive business days, triggering a notice from Nasdaq. After failing to regain compliance within the initial 180-day grace period, Immunic transferred its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, receiving an additional 180 days, until June 22, 2026, to meet the $1.00 minimum bid price for at least 10 consecutive business days. If Immunic does not regain compliance, Nasdaq may delist the company’s shares, though Immunic would have the opportunity to appeal. The company has indicated it may implement a reverse stock split if necessary to meet the requirement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL1Pdtbc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2601285830","title":"Immunic Inc. Sets New CEO Pay Package for Duane Nash","url":"https://stock-news.laohu8.com/highlight/detail?id=2601285830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601285830?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:01","pubTimestamp":1767650511,"startTime":"0","endTime":"0","summary":"Immunic Inc. has announced a new employment agreement for Dr. Duane Nash in connection with the company's subsidiary, Gliomic Therapeutics Inc. Effective January 1, 2026, Dr. Nash will serve as Chief Executive Officer and President of Gliomic, with a monthly base salary of $33,987. He will also be eligible to participate in all company benefit plans available to senior executives, and receive reimbursement for certain business-related expenses. Upon termination, Dr. Nash is entitled to a lump sum payment covering any earned but unpaid salary, six months of COBRA reimbursement, and any accrued benefits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL13BX3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2586593372","title":"Immunic Inc. CEO to Join Evercore ISI Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2586593372","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586593372?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:30","pubTimestamp":1764156621,"startTime":"0","endTime":"0","summary":"Immunic Inc. will participate in the 8th Annual Evercore ISI Healthcare Conference, taking place from December 2-4, 2025, in Coral Gables, Florida. Chief Executive Officer Daniel Vitt, Ph.D., is scheduled for a fireside chat on Thursday, December 4, 2025, at 9:35 am ET. A webcast of the event will be available on the \"Events and Presentations\" section of Immunic's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL3r8YTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EVR","BK4139","IMUX"],"gpt_icon":0},{"id":"2583570656","title":"Immunic price target lowered to $8 from $10 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2583570656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583570656?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:15","pubTimestamp":1763118939,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Immunic (IMUX) to $8 from $10 and keeps a Buy rating on the shares. The firm adjusted the compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunic-price-target-lowered-to-8-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunic-price-target-lowered-to-8-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMUX"],"gpt_icon":0},{"id":"2583577219","title":"Immunic, Inc. : H.c. Wainwright Cuts Target Price to $8 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2583577219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583577219?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:09","pubTimestamp":1763118579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nAZN4QSD57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2583513759","title":"Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2583513759","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583513759?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:36","pubTimestamp":1763058995,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on IMUX stock, giving a Buy rating on November 7. Myles Minter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/immunics-promising-market-potential-buy-rating-backed-by-vidofludimus-calciums-efficacy-safety-and-strategic-financial-path-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/immunics-promising-market-potential-buy-rating-backed-by-vidofludimus-calciums-efficacy-safety-and-strategic-financial-path-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMUX"],"gpt_icon":0},{"id":"2583595877","title":"Immunic Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583595877","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583595877?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:57","pubTimestamp":1763042220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 08:57 ET (13:57 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2583561159","title":"Biotech Immunic's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561159","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561159?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:38","pubTimestamp":1763033905,"startTime":"0","endTime":"0","summary":"Biotech Immunic's Q3 net loss widensOverviewImmunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 monthsR&D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024OutlookCompan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2583561289","title":"Immunic reports Q3 EPS (13c), consensus (18c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561289","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561289?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:35","pubTimestamp":1763033754,"startTime":"0","endTime":"0","summary":"“The third quarter was marked by our strong presence at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunic-reports-q3-eps-13c-consensus-18c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunic-reports-q3-eps-13c-consensus-18c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMUX"],"gpt_icon":0},{"id":"2583456198","title":"Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583456198","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583456198?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:33","pubTimestamp":1763033638,"startTime":"0","endTime":"0","summary":"Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 26.14 percent. This is a 45.83 percent increase over losses of $(0.24) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48829197/immunic-q3-eps-0-13-beats-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2583561661","title":"Immunic Inc. reports third quarter net loss of $25.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561661","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561661?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:31","pubTimestamp":1763033511,"startTime":"0","endTime":"0","summary":"Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2t3hDR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2583616635","title":"Immunic Inc. Reports Third Quarter 2025 Financial Results and Updates on Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2583616635","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583616635?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:31","pubTimestamp":1763033463,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9VHv0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2583569561","title":"Immunic Q3 Income From Operations USD -25.993 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX5C072F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2583561598","title":"Immunic Q3 Basic EPS USD -0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561598?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX5C072F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2583556147","title":"Immunic- Top-Line Data From Twin Phase 3 Ensure-1 and Ensure-2 Trials in Rms Expected by 2026 End","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583556147?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX5C072F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imux.com","stockEarnings":[{"period":"1week","weight":0.0919},{"period":"1month","weight":0.0738},{"period":"3month","weight":-0.0845},{"period":"6month","weight":-0.139},{"period":"1year","weight":-0.2568},{"period":"ytd","weight":0.3378}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.061205},{"month":2,"riseRate":0.416667,"avgChangeRate":0.020388},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.045158},{"month":4,"riseRate":0.272727,"avgChangeRate":0.040308},{"month":5,"riseRate":0.090909,"avgChangeRate":-0.095662},{"month":6,"riseRate":0.583333,"avgChangeRate":0.1345},{"month":7,"riseRate":0.583333,"avgChangeRate":0.054248},{"month":8,"riseRate":0.583333,"avgChangeRate":-0.042104},{"month":9,"riseRate":0.5,"avgChangeRate":-0.073457},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.035316},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001684},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021046}],"exchange":"NASDAQ","name":"Immunic, Inc.","nameEN":"Immunic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunic, Inc.,IMUX,Immunic, Inc.股票,Immunic, Inc.股票老虎,Immunic, Inc.股票老虎国际,Immunic, Inc.行情,Immunic, Inc.股票行情,Immunic, Inc.股价,Immunic, Inc.股市,Immunic, Inc.股票价格,Immunic, Inc.股票交易,Immunic, Inc.股票购买,Immunic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}